Pregnancy-specific glycoproteins (PSGs) are immunoglobulin superfamily members related to the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family and are encoded by ten genes in the human. They are secreted at high levels by placental syncytiotrophoblast into maternal blood during pregnancy, and are implicated in immunoregulation, thromboregulation, and angiogenesis. To determine whether PSGs are 2 expressed in tumors, we characterized 16 novel monoclonal antibodies to human PSG1 and used two that do not cross-react with CEACAMs to study PSG expression in tumors and in the gastrointestinal (GI) tract using tissue arrays and immunohistochemistry. Staining was frequently observed in primary squamous cell carcinomas and colonic adenocarcinomas and was correlated with the degree of tumor differentiation, being largely absent from metastatic samples. Staining was also observed in normal oesophageal and colonic epithelium. PSG expression in the human and mouse GI tract was confirmed using quantitative RT-PCR.
INTRODUCTION
Pregnancy-specific glycoproteins (PSGs) are abundant fetal proteins in the human maternal bloodstream during pregnancy.
1,2 The 10 PSG genes in the human, and 17 in the mouse, [3] [4] [5] are expressed predominantly in specialised secretory tissues of the placenta: human syncytiotrophoblast and rodent spongiotrophoblast and trophoblast giant cells. 6, 7 PSGs are members of the immunoglobulin gene superfamily and are closely related to another multigene family, the carcinoembryonic antigen-related cell adhesion molecule genes (CEACAM). 3, 8 CEACAMs are widely expressed in embryonic and adult tissues, and several members of the CEACAM family are expressed in tumors and used clinically as serum biomarkers and as targets for therapeutic development. [9] [10] [11] [12] [13] For example, CEA (CEACAM5) is widely used as a serum biomarker in colorectal carcinoma therapy and may be useful in monitoring pleural effusions with inconsistent cytologic results. 14, 15 There is extensive evidence of PSG mRNA expression in non-trophoblastic tumors. [16] [17] [18] [19] [20] [21] For example, in one study, PSG9 mRNA upregulation was detected in 78% (14/18) of FAP adenomas and 75% (45/60) of sporadic colorectal cancer cases tested. 21 We speculated that
PSGs may be similar to other placental hormones, such as human chorionic gonadotrophin (hCG) , that are expressed in many tumors and may contribute to tumor progression. 22 Indeed, the proposed anti-inflammatory and pro-angiogenic functions of PSGs suggest possible protumorigenic functions in cancer. [23] [24] [25] Moreover, the highly restricted pattern of PSG expression in the embryo, 26, 27 the evident absence of PSG protein expression in normal adult tissues, and the fact that PSGs are secreted molecules that accumulate in the bloodstream makes them attractive candidates as potential tumor biomarkers.
Due to the high similarity of PSG and CEACAM peptide sequences and the widespread expression of CEACAMs in normal tissues and in tumors, the specific detection of PSG protein expression in tumors is challenging and requires the development of well-validated PSG-specific antibodies. However, previous studies reporting PSG protein expression in tumors have not provided extensive validation of antibody specificity. BAP-3, a wellvalidated PSG-specific monoclonal antibody (mAb) has been developed, 28 but tumor studies using it have not been reported.
Here, we describe the production and characterization of novel anti-PSG1 mAbs, and their use to describe PSG protein expression in tumors and in normal tissues.
RESULTS

Characterization of anti-PSG1 monoclonal antibodies
To obtain antibodies that distinguish between PSGs and CEACAMs, sixteen mAbs PSG.01 -PSG.16 were raised against recombinant immunoglobulin Fc-tagged PSG1 (PSG1-Fc) and were tested for positive staining using immunohistochemistry (IHC) and Western blotting (WB), and for crossreactivity to CEACAMs using fluorescence-activated cell sorting (FACS). All mAbs were of the IgG1 isotype (data not shown). In preliminary experiments, six mAbs (mAbs PSG.01, PSG.03, PSG.04, PSG.05, PSG.06, PSG.11) detected a band of ~60 kD on WB of serum from pregnant women, but not from non-pregnant women or men, consistent with detection of a pregnancy-specific protein (data not shown). mAbs PSG.05 and PSG.11 were chosen for further characterization because they gave the most robust staining on WB (Fig. 1A, B ). These mAbs also produced robust staining on IHC of human placental syncytiotrophoblast, which is consistent with detection of endogenous PSGs as shown with mAb PSG.11 (Fig. 1C) . Similar staining was observed with mAb PSG.05 (data not shown).
To determine whether mAbs PSG.05 and PSG.11 cross-react with CEACAMs, we tested them in FACS experiments against a panel of CEACAM-expressing Hela cell lines as previously described. 29 Although no cross-reactivity was detected ( Fig. 2A) , we did not have a suitable positive control for sensitivity of mAbs PSG.05 and PSG.11 in these experiments because PSG1 is a secreted protein unlike CEACAMs, which are anchored to the cell surface.
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We therefore probed western blots containing a subset of Hela-CEACAM cell lines and recombinant PSG1 as a positive control with mAbs PSG.05 and PSG.11 and observed strong staining of PSG1 with no cross-reactivity to CEACAM1 and CEACAM5 (Fig. 2B ). that PSGs are strongly expressed at the crypt surface of the normal colon (Fig. 3A) and in the squamous epithelium of the normal oesophagus ( Table 1 ).
Progression from oesophageal squamous cell carcinoma to metastatic oesophageal carcinoma ( Table 2) .
Detection of PSG expression in human and mouse gastrointestinal tract using
qRT-PCR
We used qRT-PCR to determine the level of human PSG expression in the oesophagus and colon compared to whole brain and term placenta using a pair of redundant PCR primers 8 spanning PSG intron 1 that amplify all PSG family members. Consistent with our IHC studies, qRT-PCR analysis revealed that PSG was expressed in normal colon and oesophagus. Expression in the oesophagus was almost two orders of magnitude higher than in the brain and between four and five orders of magnitude lower than in term placenta.
Similarly, expression in the ascending colon was four orders of magnitude higher than in brain and between two and three orders of magnitude lower than in term placenta (Fig. 4A ).
For comparative purposes, we carried out a similar study in GI tract tissues from one male and one female C57Bl/6j mouse. Similar to the human, qRT-PCR analysis of mouse Psg expression using a set of redundant PCR primers showed that GI tract (oesophagus and ascending colon) expression is higher than brain, but approximately four orders of magnitude lower than placenta (Fig. 4B ).
DISCUSSION
We developed novel mAbs raised against human PSG1, and we extensively characterized two (mAbs PSG.05 and PSG.11) that specifically detect PSG expression and do not crossreact with CEACAMs. These mAbs were used to screen tumor arrays because of numerous reports of PSG mRNA expression in tumors. [16] [17] [18] [19] [20] [21] The restriction of PSG expression to placental trophoblast in normal individuals suggested that PSGs would be useful tumor biomarkers, particularly as they are secreted proteins and potentially detectable in the blood. The pattern of PSG expression in the GI tract detected by mAb PSG.05 and PSG.11 is similar to the expression of the CEACAMs, which are widely expressed in epithelial and myeloid cell lineages. CEACAM expression is particularly high in the GI tract, including the oesophageal squamous epithelium and colonic epithelia. 31, 32 CEACAMs are also expressed in multiple tumor types and CEACAM5 (formerly CEA) is used extensively as a biomarker in clinical oncology. 13, 33 The function of PSG expression in the GI tract is unknown, but there is increasing evidence that PSGs may have multiple functions in immunoregulation, thromboregulation, and angiogenesis. 34 Consistent with their co-expression, PSGs and CEACAMs both exhibit immunoregulatory functions. 5 An immunoregulatory function for PSGs in the GI tract is also supported by the expression of mouse Psg18 in the follicle-associated epithelium overlaying
Peyer's patches in the small intestine, 35 possibly contributing to a tolerogenic response to commensal bacteria and food antigens, or regulating immune responses to pathogens. 36, 37 The recent finding that PSGs induce and activate TGFβ1 and prevent colitis in a mouse model, 38,39 suggest a possible anti-inflammatory role in the colon. Manipulation of PSG expression in animal models will be required to test these possibilities. Human studies will be facilitated by novel anti-PSG specific mAbs reported here.
Because of the high degree of sequence identity between the 10 predicted human PSG proteins, it is likely that mAb PSG.05 and PSG.11 each detect multiple PSG family members.
This was confirmed by western immunoblot against the supernatants containing the human PSG family members, where mAb PSG.05 detected PSG1, PSG7 and PSG8, and mAb PSG.11 detected PSG1 and PSG8. BAP-3, a mAb raised against PSG purified from human retroplacental blood serum, recognises an epitope in the B2 domain and cross-reacts with all six PSG proteins, and none of seven CEA proteins, expressed in cell lines. 28 While less fully characterized and apparently less specific than the mAbs described in this study, BAP-3 may nevertheless be useful as a complement to our mAbs described herein.
The levels of PSG mRNA are approximately four orders of magnitude lower in mouse and human GI tract compared to their respective placentas, which is unsurprising given the extremely high levels of PSG expression in the placenta. 40 Notwithstanding the comparison with placenta expression, human and mouse GI tract PSG expression is two orders of magnitude higher than in brain, suggesting that GI tract expression is significantly higher than background. Combined with previous studies, our findings suggest that PSG protein expression occurs extensively in the GI tract, with implications for understanding immune, epithelial and tumor cell regulation in these tissues. 
MATERIALS AND METHODS
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PSG1 protein with a deletion of the A1 domain (PSG1ΔA1) was made as previously described. 44 Briefly, the mutated ORF was created using site-directed mutagenesis of the and 10% FCS. Supernatants of hybridomas were collected and screened against the PSG-Ig protein by ELISA using the same procedure as for the sera. Positive hybridomas were subcloned to clone density, and supernatants were collected from mAbs PSG.01 -PSG.16.
mAbs were purified from supernatants by protein G affinity chromatography using an ÄKTAprime plus system (GE Healthcare).
Commercially sourced primary antibodies were mouse anti-actin mAb and rabbit anti- qRT-PCR of mouse tissues was carried out essentially as described previously using Psgall2F/R and HprtF/R primer sets. 46 View publication stats View publication stats
